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leads to the loss of high acuity and color vision and, ultimately to blindness. In RP, a vast number
of mutations perturb the structure and function of rod photoreceptors, while cones remain initially
unaffected. Extensive rod loss in advanced stages of the disease triggers cone death by a mechanism that is
still largely unknown. Here, we show that secondary cone cell death in animal models for RP is associated
with increased activity of histone deacetylates (HDACs). A single intravitreal injection of an HDAC
inhibitor at late stages of the disease, when the majority of rods have already degenerated, was sufficient to
delay cone death and support long-term cone survival in two mouse models for RP, affected by mutations
in the phosphodiesterase 6b gene. Moreover, the surviving cones remained light-sensitive, leading to an
improvement in visual function. RNA-seq analysis of protected cones demonstrated that HDAC inhibition
initiated multi-level protection via regulation of different pro-survival pathways, including MAPK, PI3K-
Akt, and autophagy. This study suggests a unique opportunity for targeted pharmacological protection
of secondary dying cones by HDAC inhibition and creates hope to maintain vision in RP patients even
in advanced disease stages.
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Abstract
Cone photoreceptor cell death in inherited retinal diseases, such as Retinitis Pigmentosa (RP), leads to the loss of high acuity
and color vision and, ultimately to blindness. In RP, a vast number of mutations perturb the structure and function of rod
photoreceptors, while cones remain initially unaffected. Extensive rod loss in advanced stages of the disease triggers cone
death by a mechanism that is still largely unknown. Here, we show that secondary cone cell death in animal models for RP is
associated with increased activity of histone deacetylates (HDACs). A single intravitreal injection of an HDAC inhibitor at
late stages of the disease, when the majority of rods have already degenerated, was sufficient to delay cone death and support
long-term cone survival in two mouse models for RP, affected by mutations in the phosphodiesterase 6b gene. Moreover, the
surviving cones remained light-sensitive, leading to an improvement in visual function. RNA-seq analysis of protected cones
demonstrated that HDAC inhibition initiated multi-level protection via regulation of different pro-survival pathways,
including MAPK, PI3K-Akt, and autophagy. This study suggests a unique opportunity for targeted pharmacological
protection of secondary dying cones by HDAC inhibition and creates hope to maintain vision in RP patients even in
advanced disease stages.
Introduction
In Retinitis Pigmentosa (RP), the leading cause of inher-
ited blindness, mutations in more than 90 genes affect the
survival and/or function of rod photoreceptors or retinal
pigment epithelium cells (RPE) (http://www.sph.uth.tmc.
edu/Retnet/home.htm). One of the particularities of RP is
that despite being mutation-unaffected, cone photo-
receptors die secondarily once most rods are lost [1]. In
humans, loss of rods initially has only minor con-
sequences for vision, and the majority of patients are
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unaware of their condition until they start experiencing a
prominent reduction in the central visual field, acuity, or
color discrimination, due to the loss of cones. Hence, in a
clinical setting, it is highly pertinent to develop therapies
to treat advanced stages of RP, when the majority of rods
have already degenerated, and cone degeneration has set
in [2].
Despite the importance of cones for human vision, stu-
dies on therapeutic options to prevent their loss at advanced
stages of RP are disproportionally low [1, 3–6] due to the
intercellular relationship between rod and cone photo-
receptors in human and mouse retina, where cones represent
less than 5% of all photoreceptors [7]. Moreover, current
knowledge suggests that the massive loss of rods in late RP
creates a “point of no return”, after which cone cell death is
unstoppable [2, 8], as cones are suffering from the loss of
structural and nutritional support from rods [1, 9], exposure
to oxidative stress [4], and inflammation [3, 6]. Although
alleviating each of these processes individually has the
potential to preserve cones to some extent [1, 3, 5, 10], an
ideal therapeutic option should provide multi-level protec-
tion of cones in the rod-depleted retina. One way to achieve
this could be by an epigenetically driven simultaneous
regulation of several genes involved in diverse pro-survival
responses.
Histone deacetylases (HDACs) are regulators of the
chromatin structure, and changes in their activity affect
transcription of a number of genes [11]. Tightly packed
chromatin, following the HDAC-governed removal of
acetyl groups from histones, is generally associated with
transcriptional silencing, albeit this largely depends on the
type and “health” status of cells [12]. Aberrant HDAC
activity is causatively linked to various diseases ranging
from cancer, to neurodegenerative diseases [12, 13]. We
and others have previously shown that epigenetic regula-
tion, via HDAC inhibition, can protect primary degenerat-
ing photoreceptors in inherited retinal dystrophies caused by
mutations in different genes [14–17]. Consequently, more
than 90 clinical trials involving HDAC regulators stress
HDAC inhibition as a promising therapeutic approach for
various diseases, including retinal dystrophies [12, 18].
Here, we investigated the involvement of HDACs in
secondary cone degeneration in mouse models of RP. We
found an increased HDAC activity present in both
mutation-affected rods and in secondary dying cones. A
single intravitreal injection of the HDAC inhibitor Tri-
chostatin A (TSA) afforded long-term preservation of cone
photoreceptors. Transcriptional changes associated with
cone survival comprised regulation of distinct pro-survival
mechanisms, including autophagy, MAPK, and PI3K/Akt
regulation. Thus, therapies based on HDAC inhibition can
offer a unique possibility to attenuate the loss of photo-
receptors independent of the stage of degeneration.
Materials and methods
Animals
The C3H rd1/rd1 (rd1), C57BL/6J x C3H HR2.1:TN-XL x
rd1 (rd1TN-XL), C57BL/6J rd10/rd10 (rd10), and C57BL/6J
wild-type (wt) mice were housed under standard light
conditions, had free access to food and water, and were used
irrespective of gender. rd1TN-XL mice express the TN-XL
(Ca2+ biosensor) selectively in cone photoreceptors under
the control of the human red opsin promoter (HR2.1)
[19, 20]. The presence of TN-XL biosensor does not alter
the rd1 phenotype, while it enables direct visualization of
cone photoreceptors by fluorescence microscopy [20]. All
procedures were performed in accordance with the ARVO
statement for the Use of Animals in Ophthalmic and Vision
Research, the regulations of the Tuebingen University
committee on animal protection, Germany, veterinary
authorities of Kanton Zurich, Switzerland and the ethics
committees of the CSIC and the Comunidad de Madrid.
Intravitreal injections
Single intravitreal injections were performed at postnatal
day (PN) 19 in rd1TN-XL and PN42 in rd10 mice, as pre-
viously described [14]. Mice were anesthetized sub-
cutaneously with a mixture of ketamine (85 mg/kg) and
xylazine (4 mg/kg). One eye was injected with 0.5 µl of a
100 nM TSA (catalog T8552, Sigma-Aldrich, St. Louis,
MO) in 0.0001% DMSO, while the contralateral eye was
sham-injected with 0.0001% DMSO and served as a con-
trol. Assuming the intraocular volume of mouse eye to be
5 µl [21], this procedure resulted in a final intraocular
concentration of 10 nM TSA. For the open field behavioral
test, rd10 littermates were TSA- or sham-injected bilaterally
at PN42.
Retinal explant cultures
Organotypic retinal cultures from rd1TN-XL animals,
including the retinal pigment epithelium (RPE) were pre-
pared under sterile conditions as previously described
[14, 15]. PN19 or PN21 rd1TN-XL animals were sacrificed,
the eyes enucleated and pretreated with 0.12% proteinase K
(ICN Biomedicals Inc.) for 15 min at 37 °C in HBSS
(Invitrogen Inc.). Proteinase K activity was blocked by the
addition of 10% fetal bovine serum, followed by rinsing in
HBSS. Next, the cornea, lens, sclera, and choroid were
removed, while the RPE remained attached to the retina.
The explant was cut into a clover-leaf shape and transferred
to a culture membrane insert (Corning Life Sciences) with
the RPE facing the membrane. The membrane inserts were
placed into six-well culture plates with Neurobasal-A
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medium (catalog 10888022) supplemented with 2% B27
(catalog 0080085-SA), 1% N2 (catalog 17502048), and
L-glutamine (0.8 mM, catalog 25030032) (all from Invi-
trogen Inc.), and incubated at 37 °C in a humidified 5%
CO2 incubator. The culture medium was changed every
2 days during the 7 days culturing period. Retinal explants
were treated with 10 nM TSA, 1 µM Panobinostat (catalog
S1030, Selleckchem), 20 µM LY294002 (catalog S1105,
Selleckchem), and 10 µM U0126-EtOH (catalog S1102,
Selleckchem) diluted in Neurobasal-A culture medium. For
the PI3K-Akt and MAPK inhibition experiments, cultures
were treated with TSA, LY294002, U0126, TSA+
LY294002, and TSA+U0126 only for 2 days followed by
the culture medium without compounds for additional
5 days. For controls, the same amounts of DMSO were
diluted in the culture medium. Culturing was stopped after
7 days by 2 h fixation in 4% PFA, cryoprotected with gra-
ded sucrose solutions containing 10, 20, and 30% sucrose
and then embedded in tissue freezing medium (Leica
Microsystems Nussloch GmbH).
Quantification of cone survival
The quantification of cones was performed by manually
counting the number of TN-XL labeled cones (using the Zen
event counter) on at least two retinal cross-sections cut along
the dorsoventral axis, at the level of the optic nerve. Retinal
cross-sections were used to quantify cone photoreceptors as
the TN-XL biosensor is present throughout the cone photo-
receptor, except the outer segment (IS) [19]. The presence of
the biosensor in the cell body, axon and IS, hampers a clear
separation of individual cell bodies from the IS and/or axon
on flat-mount preparations at the late stages of rd1TN-XL
degeneration, where cones align horizontally to the INL due
to the lack of structural support from rods (SI Appendix, Fig.
S1A.) Retinal cross-sections with labeled nuclei enabled dis-
tinction between different parts of the cones and facilitated the
counting of their cell bodies. Colabeling of rd1TN-XL cones
with a cone-specific antibody, cone arrestin (CAR), showed
full overlap between two fluorescent signals confirming the
specificity of TN-XL labeling both in degenerating and pro-
tected cones (SI Appendix, Fig. S2). Cones were quantified
on multiple images projection (MIP) obtained from 9–15
optical sections taken with 20x magnification at four positions
in the retina: ventral and dorsal central retina (corresponding
to −10° and 10° of eccentricity from the optic nerve,
respectively) and ventral and dorsal peripheral positions at
−80° and 80° degrees (SI Appendix, Fig. S1). For the
quantification of cone survival in rd10 retinas, cones were
labeled with an antibody against cone arrestin. Spider dia-
grams show the number of cones per 100 µm of the outer
nuclear layer (ONL) length at each position, presented as
mean values ± SEM.
Histology
For retinal cross-sectioning, the eyes were marked
nasally, and eyecups (after cornea, iris, lens, and vitreous
removal) were fixed in 4% paraformaldehyde for 2 h at
room temperature. Following graded sucrose cryoprotec-
tion eyes were embedded in optimal cutting temperature
compound (Tissue-Tek), cut into 12 μm sections, and
mounted with Vectashield medium containing 4’,6-dia-
midino-2-phenylindole (DAPI, Vector). For retinal flat
mounts, retinas without RPE were fixed for 30 min, cut
into a cloverleaf shape, and mounted with Vectashield
with the photoreceptors facing up. To analyze retinal
morphology, eyes were fixed in 2.5% glutaraldehyde, cut
at the optic nerve level, followed by 1% osmium tetroxide
treatment post-fixation and ethanol dehydration, accord-
ing to a previously described protocol [22]. After
embedding in Epon 812, 0.5 μm thick sections were
counterstained with toluidine blue. Immunostaining was
performed on retinal cryosections by incubating with
primary antibodies against rabbit cone arrestin (1:1000;
catalog AB15282, Merck Chemicals GmbH), mouse anti-
rhodopsin (1:400, catalog MAB 5316, Chemicon), LC3B
(1:100, catalog NB-100-220, Novus) and LAMP1 (1:100,
clone 1D4B, DSHB) at 4 °C overnight. Alexa Fluor 488,
568, or 647-conjugated antibodies were used as secondary
antibodies. Images were captured using Z-stacks on a
Zeiss Axio Imager Z1 ApoTome Microscope using 20x
air, 40x oil, or 100x oil objectives. For the quantification
of the LC3 and LAMP1 puncta in cones, 4 images per
retina for in vivo treatment and 8 images per explant were
assessed in each confocal plane obtained by the Leica
TCS SP5 Confocal Microscope. Colocalizing puncta were
counted using the counter plugin of Image J. The number
of colocalizing puncta was divided by the number of
cones in the whole z-stack.
HDAC in situ activity assay
HDAC activity assays were performed on 12 µm thick
cryosections of 4% PFA- fixed eyes following immunos-
taining against cone arrestin/rhodopsin as previously
described [14]. Briefly, retina sections were exposed to
200 μM Fluor de Lys-SIRT2 deacetylase substrate (Biomol)
with 500 μM NAD+ (Biomol) in assay buffer (50 mM Tris/
HCl, 137 mM NaCl; 2.7 mM KCl; 1 mM MgCl2; pH 8.0)
for 3 h at room temperature. Following methanol fixation at
-20 °C for 20 min, a developer solution (1x Biomol; KI105)
containing 2 μM TSA and 2 mM nicotinamide in assay
buffer was applied to generate the signal. Due to the pre-
sence of a background staining in negative controls, only
cells with prominent nuclear staining were considered as
HDAC positive [14].
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MEA recording
Retina explant cultures attached to the membrane were
transferred from the incubation chamber to a 256-electrode
MEA (Multi channel systems MCS GmbH, Reutlingen,
Germany) with the ganglion cell side facing the electrodes.
A custom-made grid was placed over the retina to improve
the contact between electrodes and the tissue and the sta-
bility of the recording. Cultures were perfused throughout
the experiment with oxygenated Ames’ medium (A1420,
Sigma-Aldrich) and heated to 36 ˚C. The electrode spacing
was 200 µm, with the total recordings area of ~3.2 × 3.2
mm2. Twenty repetitions of 350 ms long light-flashes of
increasing intensity (8.6 e12, 5.3 e13, 3 e14, 8.7 e14, 1.6
e15, 2.3 e15 photons/cm2 s) separated by 2 s of dark were
presented to both control and the TSA-treated retinal
explants mounted on MEA. The recordings were made with
a sampling rate of 25 kHz using the MC Rack software
(Multi Channel Systems MCS GmbH). The analysis of
recordings from 256-MEAs was performed using Python
3.6. Recordings were bandpass - filtered (400–5000 Hz,
Butterworth 2nd order), and spikes were detected as
threshold crossing of 5 times the standard deviation of the
filtered signal with a pause time of 1.5 ms. Light-induced
RGCs activation recorded by an electrode was quantified
for each light intensity using a two-tailed, paired t-test
comparing the detected spikes during the 20 repetitions of
light-ON (350 ms of light flash) or light-OFF (350 ms after
the light shut-off) versus the spontaneous activity recorded
before light onset. Only electrodes with a statistically sig-
nificant difference (p < 0.01 and t-statistic > 2) were con-
sidered light-activated. In addition, only channels light-
activated for at least 3 out of 5 light intensities in the
photopic light range (5.3 e13, 3 e14, 8.7 e14, 1.6 e15, 2.3
e15 photons/cm2) were included in the analysis. These
criteria were used to eliminate potential non-stable record-
ings. To quantify the degree by which light onset changes
the spontaneous firing rate and to avoid an overestimation
of the electrodes recording low spontaneous activity, a
response ratio was calculated. The calculation is based on
the well-established bias index used to quantify physiolo-
gical light responses [23, 24] and is analogous to the
Michelson contrast used to quantify the contrast in visual
images:
Response ratio= (Firing rate LIGHT ON – Firing rate
spontaneous)/(Firing rate LIGHT ON+ Firing rate
spontaneous).
Open field behavioral test
The open field test is based on natural mouse behavior to
avoid brightly lit open spaces [25]. This test was performed
based on the previously described procedure with minor
modifications [26]. A custom-made box for light/dark
transition test (60 × 30 × 30 cm) was divided into two
chambers, one black and one white, connected by a door
(5 × 5 cm). The mice were habituated in the dark for at least
1 h before the testing. The light chamber was illuminated
from the top by white diodes (670 lux, LitePad® HO90,
Rosco). Mice were placed into the dark compartment, and
the door was opened after 3 s. Mice were allowed to move
freely between the two chambers with the door open for 5
min. The time spent in the dark chamber was registered by
an experimenter. After each trial, all chambers were disin-
fected to prevent a bias based on olfactory cues.
ERG recordings
Mice were dark adapted overnight, and subsequent manip-
ulations were performed in dim red light. Mice were anes-
thetized with intraperitoneal injections of ketamine (95 mg/
kg) and xylazine (5 mg/kg) solution and maintained on a
heating pad at 37 °C. Pupils were dilated with a drop of 1%
tropicamide. To optimize electrical recording, a topical drop
(2% Methocel) was applied to each eye immediately before
placing the corneal electrode. Flash-induced ERG responses
were recorded from the right eye in response to light stimuli
produced with a Ganzfeld stimulator. Light intensity was
measured with a photometer at the level of the eye (Mavo
Monitor USB). Four to 64 consecutive stimuli were aver-
aged with an interval between light flashes in scotopic
conditions of 10 s for dim flashes and up to 60 s for the
highest intensity. Under photopic conditions, the interval
between light flashes was fixed at 1 s. ERG signals were
amplified and band-filtered between 0.3 and 1000 Hz with
an amplifier (CP511 AC amplifier). Electrical signals were
digitized at 20 kHz with a power laboratory data acquisition
board (AD Instruments). Under dark adaptation, scotopic
threshold responses (STR) were recorded to light flashes of
−4 log cd·s·m−2; rod responses were recorded to light fla-
shes of −2 cd·s·m−2, and mixed responses were recorded in
response to light flashes of 1.5 log cd·s·m−2. Oscillatory
potential (OP) was isolated using white flashes of 1.5 log
cd·s·m−2 in a recording frequency range of 100–10,000 Hz.
Under light adaptation, cone-mediated responses to light
flashes of 2 log cd·s·m−2 on a rod-saturating background of
30 cd·m−2 were recorded. Wave amplitudes of the STR, rod
responses (b-rod), mixed responses (a-mixed and b-mixed),
and OP were measured offline by an observer masked to the
experimental condition of the animal.
Flow-sorting of the cone photoreceptors
A protocol from Palfi et al. [27]. was used to dissociate
retinal cells. Briefly, PN19-26 control and TSA-treated
retinal explant cultures were removed from membranes and
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incubated in trypsin (Sigma-Aldrich) solution for 20 min at
37 °C. Following incubation with trypsin inhibitor (Sigma-
Aldrich), cell suspension was washed with HBSS and
passed through a 40-µm filter before fluorescence activated
sorting (FACS). One biological replicate included at least 2
retinal explants prepared from different animals. Three
independent biological replicates from control and TSA-
treated retinal explants were used for cone photoreceptor
FACS using an ARIAIII cell sorter (BD Biosciences). The
sort was performed with a 100 µm nozzle tip, at a sheath
pressure of 20.0 psi, and with purity precision. TN-XL
positive cone photoreceptors were gated as follows: singlets
forward scatter (FSC-A vs FSC-H)/singlets side scatter
(SSC-A vs. SSC-H)/viable cells (FSC-A vs. SSC-A)/TN-
XL+ cells (FSC-A vs. TN-XL-A) (gating Fig. S5A, B).
The purity of sorted TN-XL+ cells was checked by per-
forming post-sort FACS analysis (Fig. S5C, D).
Whole transcriptome sequencing and data analysis
2000–5000 frozen sorted-cells were lysed in ~10 µl of lysis
buffer, and cDNA synthesis was performed using the
SMART-Seq v4 Ultra Low Input RNA Kit (catalog 634888,
Takara Bio). First-strand cDNA synthesis was performed
using 20–50% of the input, and was followed by full-length
double-strand cDNA amplification using 17 PCR cycles.
The quality of the resulting cDNA was validated using
Bioanalyzer and High Sensitivity DNA Kit (Agilent), and
Qubit dsDNA HS fluorometric quantification (Thermo-
Fisher Scientific). NGS libraries were prepared using 150 pg
of cDNA input and the Nextera XT DNA Library Pre-
paration Kit (catalog FC-131-1024, Illumina) with 11 cycles
of PCR. Libraries were sequenced as single reads (75 bp
read length) on a NextSeq500 (Illumina) with a depth of
>20 million reads. Library preparation and sequencing
procedures were performed by the same individual, and a
design to minimize technical batch effects. Data quality of
raw RNA-seq reads in FASTQ files was assessed using
ReadQC (ngs-bits version 2018_04) to identify potential
sequencing cycles with low average quality and base dis-
tribution bias. Reads were preprocessed with Skewer (ver-
sion 0.2.2) and aligned using STAR (version 2.5.4a),
allowing spliced read alignment to the mouse reference
genome (Ensembl Mus musculus GRCm38). Alignment
quality was analyzed using MappingQC (ngs-bits version
2018_04) and visually inspected with Broad Integrative
Genome Viewer (version 2.4.0). Based on the genome
annotation ITAG (Ensembl 75), normalized read counts for
all genes were obtained using subread (version 1.6.0) and
edgeR (version 3.28.0). Raw counts data were processed
using iDEP, an integrated web application for RNA-seq
data analysis [28]. To provide access to RNAseq data, we
generated a BioJupies notebook [29] link providing an
interactive and visual analysis of all the data (https://amp.
pharm.mssm.edu/biojupies/notebook/LjknTl51J). Sequen-
cing data are deposited on GEO with the accession number
GSE141601.
For differential gene expression (DEG) analysis, gene
counts were filtered to only retain genes with a value > 1
cpm (count per million), in at least two samples within at
least one group (control or treated), leaving around 14,400
genes for determination of differential expression in each of
the pair-wise comparisons between experimental groups.
Differentially expressed genes between treated and control
groups were identified using the two-tailed permutation
FDR-based Student’s t test (FDR < 0.05 and 250 randomi-
zations). Only transcripts coding for protein sequences were
retained for pathway analysis. Quantitative gene expression
data was submitted and integrated into the PaintOmics 3
data analysis platform [30, 31], in order to identify trends in
pathway modulation following the TSA treatment. A stable
link is provided to access and visualize the results
(http://www.paintomics.org/?jobID=4CIbSr1eA4).
Quantitative RT-PCR
For qRT-PCR, 2000–6000 cones from two pooled PN19-
26 ex vivo rd1TN-XL explants were sorted in 350 µl RLT
buffer (Qiagen) to lyse cells. RNA extractions were per-
formed using an RNeasy Micro Kit (Qiagen), followed by
cDNA synthesis using the QuantiTect Reverse Tran-
scription Kit (Qiagen). qRT-PCR reactions were per-
formed in technical duplicates of 4 biological samples of
TSA-treated and control retinas, on BioRad CFX96 real-
time system using QuantiTect SYBR Green PCR Kit
(Qiagen) along with gene specific forward (fwd) and
reverse (rev) primers (250 nM). The sequences of the
primer sets used are listed in supporting Table S1. The
PCR protocol included 40 cycles of: 94 °C (15 s), 57 °C
(30 s), and 72 °C (30 s). Relative mRNA expression of
each gene of interest was calculated using ΔΔCT method
and GAPDH as a housekeeping gene.
Statistics
All data were analyzed using Excel (Microsoft) and
GraphPad Prism 6. For each comparison between control
and treated groups, normal distribution was determined with
GraphPad software (D’Agostino & Pearson omnibus and
Shapiro–Wilk normality tests). When applicable (metho-
dology based) investigators were blinded for the condition.
Quantification of in vivo survival for every time points, for
different positions, was calculated using two-way ANOVA.
The overall temporal survival curve shown in Fig. 2R was
obtained by averaging all the analyzed positions from all the
animals per stage. The statistical significance in the
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broadening of the survival curves was assessed via shared
control Cummings estimation plot using the DABEST
package in R with 5000 bootstraps resamples (https://www.
estimationstats.com/) [32]. A shared-control estimation plot
represents the Hedges’ g comparison of log2-transformed
cone survival ratios. Since TSA treatment prevented
rd1TN-XL cone loss up to 7 days post-injection, the cone
survival ratio at PN26 was used as the control and compared
to the survival ratio at PN30, PN37, PN45, PN60 and PN90.
The statistical significance of Hedges’ g difference was deter-
mined by unpaired two-sided permutation t-test.
Ex vivo survival was quantified on 5–12 different posi-
tions, from 3–5 retinal cross-sections obtained from differ-
ent positions within a retinal explant. Unpaired, two-tailed
t-tests were used to compare controls with treatments.
Statistical differences for LC3-LAMP1 puncta quantifi-
cation and qRT-PCR were calculated using Mann–Whitney
nonparametric test.
RNAseq raw data were processed and normalized using
subread (version 1.6.0) and edgeR (version 3.28.0). Statistical
data analysis was carried out using the Perseus tool suite for
Omics data analysis [33]. Two-tailed, unpaired permutation-
based FDR Students’ t test on biological replicates’ mean
difference was applied (FDR< 0.05 and 250 randomizations).
Log2 fold changes, mean differences, and p values are reported
in the Gene expression dataset.
The statistical difference of light-induced response ratio
between control and treated retinas was calculated using a
Wilcoxon rank-sum test.
Statistical difference of open field behavioral test was
calculated using a two-way ANOVA test.
Results
Secondary cone degeneration in RP is associated
with an increased HDAC activity
To assess the involvement of HDACs in the secondary cone
degeneration, we used an HDAC in situ activity assay [16] at
advanced stages of photoreceptor degeneration in two mouse
models for RP, the rd1 and rd10 mice. Different mutations in
the rod-specific phosphodiesterase 6b (Pde6b) gene lead to fast
rod photoreceptor degeneration, with the onset at PN9 in rd1
and PN14 in rd10 mice [15, 34, 35]. Cone degeneration begins
once most rods have degenerated, around PN20 in the rd1 and
PN40 in the rd10 mouse [1, 3]. At PN30, the outer nuclear
layer (ONL) in rd1 mice is reduced to only one row of pho-
toreceptors, almost exclusively cones (Fig. 1A).
A combination of in situ HDAC activity assay with cone-
and rod-specific immunostaining confirmed previously estab-
lished association of increased HDAC activity and rod
degeneration (Fig. 1A) [15, 16]. Interestingly, HDAC activity
also colocalized with the cones, once the majority of rods have
degenerated (Fig. 1A–A”) [1]. The presence of HDAC positive
cells within the ONL was detected through the entire period of
cone cell death in rd1 mice (Fig. 1C), while no positive signal
for HDAC activity was detected in nuclei of wild-type mice at
PN30 (Fig. 1B). Moreover, late stages of rd10 degeneration
also displayed increased HDAC activity, mirroring the timeline
of photoreceptor cell death in the rd10 mouse, characterized by
massive rod loss up to PN26 [35], followed by continuous
photoreceptor cell death, likely reflecting the simultaneous rod
and cone loss (Fig. 1D, E). These findings suggest that the cell
Fig. 1 Increased HDAC activity in RP photoreceptors at advanced
stages of degeneration. A–A” HDAC in situ activity assay in rd1
retinal cross-sections at PN30. HDAC activity (blue) was present in
both rod (magenta, arrowhead, rhodopsin immunostaining) and cone
photoreceptors (green, arrow, cone arrestin immunostaining). A’
Magnification of the marked region indicating HDAC+ cell coloca-
lizing with cone arrestin (A”). B HDAC activity in wild-type retina at
PN30. C Percentage of TUNEL+ and HDAC+ cells in the ONL of
rd1 and wt mice over time. D–D” Representative image of a coloca-
lization of HDAC activity and cone arrestin in rd10 mice at PN59,
with only cones remaining in the ONL. E Percentage of TUNEL+ and
HDAC+ cells in the ONL of rd10 and wt mice over time. Data are
shown as mean ± SEM (n= 3–5 animals per age). Scale bars: 50 µm.
ONL outer nuclear layer, INL inner nuclear layer, GCL ganglion cell
layer, PN post-natal day.
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death of both mutation-affected rods and secondary dying
cones may be associated with HDAC overactivation.
HDAC inhibition prolongs cone survival in RP mice
To determine if HDAC inhibition has the potential to
prevent secondary cone degeneration, we injected a well-
established class I and II HDAC inhibitor, TSA, in the
rd1TN-XL mouse that expresses the fluorescent TN-XL
biosensor exclusively in M- and L-cones [19] (Figs. S1,
S2). To minimize the indirect positive effects of increased
rod survival afforded by HDAC inhibition on the rd1 cone
survival, we selected a late time-point to start the treat-
ment, PN19. Already from PN19, the rd1TN-XL ONL is
reduced to only one row of photoreceptors, almost
exclusively cones (Fig. 2A). After a single intravitreal
injection of TSA at PN19, we assessed cone survival up to
3 months of age at different time points: PN26, PN30,
PN37, PN45, PN60, and PN90. Whole-mount prepara-
tions of sham-injected eyes showed center to periphery
gradient of cone loss at PN30 (Fig. 2B). In contrast, an
increased cone-specific fluorescent signal was detected in
Fig. 2 HDAC inhibition promotes long-term cone survival in
rd1
TN-XL mice. A Retinal cross-section of an rd1TN-XL mouse at PN19,
showing TN-XL-labeled cones (green), rods (magenta, anti-rhodopsin
antibody), and nuclei (gray, DAPI). Note that the mouse secondary
antibody used to detect anti-rhodopsin antibodies showed the non-
specific signal in layers other than ONL. Schematic representation of a
single intravitreal injection of TSA at PN19, followed by quantifica-
tion of cone survival up to PN90. B–G Flat mounted retinas from
control and TSA-treated eyes at indicated PN days. H–M Repre-
sentative images of retinal cross-sections from control and TSA-treated
retinas at PN30, PN60 and PN90 used to quantify of TN-XL labeled
cones. H’–M’ Magnifications of the marked regions shown in H–M.
N–Q Retinal morphology of control and treated retinas at PN30 and
PN60. R Quantification of cone survival in control and TSA-treated
retinas. Y axis is in log2 scale. Data are shown as means ± SEM (n=
5–10 animals per age). Numerical p values by two-way ANOVA. The
fitting of the exponential curves is shown in dotted lines. Scale bars: A,
H–M 50 µm; B–G 500 µm; H’–M’20 µm; N–Q 10 µm. ONL outer
nuclear layer, INL inner nuclear layer, GCL ganglion cell layer, PN
postnatal days.
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treated contralateral eyes (Fig. 2C). While at PN60 and
PN90, loss of cones had proceeded in control eyes, with
cones remaining only at the far periphery (Fig. 2D, F), the
treated eyes showed higher immunofluorescent signals,
suggesting enhanced cone preservation in the central
retina up to 3 months of age (Fig. 2E, G). An increase in
cone survival was even more evident on retinal cross-
sections, where individual cone cell bodies and remaining
cone segments could be clearly identified (Figs. 2H–M’,
S1, S2). A higher number of cones in TSA-treated animals
was also evident in retinal light micrographs (Fig. 2N–Q).
While untreated retinas showed a reduced density of
nuclei, many of which were pyknotic, the treated retina
displayed healthier cone morphology with classical het-
erochromatin distribution (Fig. 2O, Q) [22]. A single
intravitreal injection was sufficient to prevent loss of
rd1TN-XL cones for up to 7 days, while in control retinas,
cone degeneration continued with ~15% fewer cones than
at the beginning of the treatment. A plot of cone numbers
up to PN90 showed that cone loss in control and treated
retinas followed an exponential decay function, with the
two curves clearly separated (Fig. 2R). In addition, fitted
trend lines showed significantly broader separation of the
two curves at PN90 (Figs. 2R and S3) and predicted an X-
axis intersection of the treated curve with a delay of
16 days, compared to control (PN79 for treated vs. PN95
for control retinas, Fig. 2R). These extrapolations suggest
that the TSA treatment not only delayed but also slowed
down secondary cone degeneration.
To analyze the effects of continuous TSA treatment on
cone survival, we treated rd1TN-XL retinal explants from
PN19 until PN26 ex vivo. Retinal cultures, consisting of the
retina and RPE layer, enable maintaining mature neurons
in situ, and complex neuronal connections while providing
the possibility for constant exposure to a drug via a culture
medium (Fig. 3A). Similarly to rd1TN-XL cone degeneration
in vivo, the center to periphery gradient of cone loss was
more prominent in the control explant cultures (Fig. 3B).
Quantification of cone numbers in retinal cross-sections
showed ~30% increase in the cone survival in TSA-treated
retinal explants (Fig. 3B).
Next, we asked if the HDAC inhibition has the potential
to protect secondary dying cones even at a later stage of
degeneration. For this, we started the treatment at PN21 and
assessed the rd1TN-XL cone survival after one week in culture
(Fig. 3C). Also in this case, the TSA treatment significantly
improved cone survival, with 52% more cones in the treated
explants. We also tested the neuroprotective properties of
Panobinostat, a clinically approved pan-HDAC inhibitor
within the same group of inhibitors as TSA [36]. As with
TSA, 7 days treatment with Panobinostat increased rd1TN-XL
cone survival up to 30% (Fig. S4).
HDAC inhibition improves cone-mediated light-
responses
We then wanted to see whether the remaining cones were
light-sensitive and able to drive functional responses. We
used a micro-electrode array (MEA) [37] to record the light‐
mediated spiking activity of retinal ganglion cells (RGCs)
of rd1TN-XL retinal explants. The experimental setup inclu-
ded a light source at the bottom of the MEA chamber,
mimicking the physiological situation where light stimula-
tion comes from the ganglion cell side, while the RPE layer
Fig. 3 HDAC inhibition protects rd1TN-XL cones ex vivo. A Sche-
matic representation of the ex vivo retinal explants preparation. Reti-
nas from rd1TN-XL mice were collected at PN19 or PN21 and treated for
7 days with control or TSA-medium. B–C Representative flat mount
preparations and cross-sections of explanted retinas, that were used for
the quantification of cone survival, shown in the dot plot below. Data
are shown as mean ± SEM (n= 5–7 animals per age group). Numer-
ical p values by unpaired, two-tailed t-test. Scale bars in whole mounts
500 µm; retinal cross-sections 50 µm. RPE retinal pigment epithelium,
ONL outer nuclear layer, INL inner nuclear layer, GCL ganglion cell
layer, PN postnatal day.
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on the top of explants provided a physiological environment
for light absorption (Fig. 4A).
A LED emitting green light (505 nm) with increasing
light intensities, far below the safety limit for the human eye
[38], was used to stimulate cones in control and TSA-
treated PN19-26 retinal explants. Light-ON and Light-OFF
responses were detected in both control and treated retinas
suggesting preservation of physiological network function-
ality (Fig. 4B). To estimate the degree of activity change
upon light stimulation, we calculated a light-induced
response ratio for ON responsive MEA electrodes. The
light-induced response ratio quantifies how much the firing
rate (Fig. 4C) increases during light stimulation and can be
considered a simple link between the number of rescued
cones and functional readout. The distribution of the light-
induced response ratio, presented as a violin plot, demon-
strates that increasing light intensities lead to a higher firing
rate (Fig. 4D). Changes of the spontaneous activity under
the same light intensities were not detected. For each con-
dition (control vs. treatment), the light-induced response
ratio of the two distributions were compared. While for low
intensities, the median values in control and treated retinas
were not significantly different, the light-induced response
ratio increased in the treated samples and was significantly
different above a light intensity of 8.7 e14 photons/cm2 sec
(p < 0.01). The median light-induced response ratio in
Fig. 4 HDAC inhibition improves cone function in rd1TN-XL retinal
explants. A A micro-electrode array (MEA) with 256 electrodes was
used to record retinal ganglion cell (RGC) responses in control and
TSA-treated PN19-26 rd1TN-XL retinal explants. Schematic drawing of
the MEA setup used in the study. B Representative recordings of ON
and OFF responses from TSA-treated retinal explants during stimu-
lation with flickering light (350 ms flashes, 505 nm) shown as raster
plots. Each dot indicates one spike. The green bar indicates the start of
light stimulation. C Exemplary spike responses obtained in ontrol
(gray) and treated (green) explants at six different light intensities,
shown as raster plots (bottom) and averaged firing rate histograms
(top). D Quantification and discrimination of the response ratio in
control (gray) and treated explants (green). Significant differences
based on Wilcoxon rank-sum test are detected for three high light
intensities (n= 161 channels from eight control, n= 274 from nine
treated retinas, **p < 0.01). RPE retinal pigment epithelium, PR pho-
toreceptors, HC horizontal cells, BC bipolar cells, AC amacrine cells,
RGC retinal ganglion cells.
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treated retinas reached 0.82 while in control condition it
approached 0.74 (Fig. 4D).
To determine if HDAC inhibition has the potential to
delay secondary cone death and preserve visual function
independent of the underlying mutation, we injected rd10
mice at a stage when the majority of rods have degener-
ated [1, 3]. A single intravitreal injection at PN42 resulted
in a higher number of cones in TSA-treated compared to
sham-treated retinas (Fig. 5A–C). Increased cone survival
was accompanied by amelioration of vision-mediated
behavior of rd10 animals injected bilaterally with TSA
(Fig. 5D, E). An improvement in cone function was also
detected by electroretinography (ERG). At PN50, a
modest but significant increase in photopic b-wave
amplitudes was detected in TSA-treated retinas (Fig. 5F,
G). Collectively our data suggest that HDAC inhibition
has the potential to support cone survival and function at
late stages of photoreceptor degeneration in different RP
mouse models.
HDAC inhibition induces global changes in gene-
transcription patterns in the surviving cones
We performed whole transcriptome analysis of flow-sorted
rd1TN-XL cones from retinal explants after seven days in
culture (PN19-26). TN-XL-positive cells represented 95%
of FASC-sorted cells, suggesting a highly purified cone
population (SI Appendix, Fig. S5). RNA-seq analysis of
differentially expressed genes (DEG) in TSA-treated vs.
untreated cones revealed 1845 genes with significantly
different expression (enrichment of 1163 and reduction in
682 genes), as indicated in the volcano plot (Fig. 6A,
Supplementary gene expression dataset). To identify sig-
nature trends for activation or inhibition of downstream
Fig. 5 HDAC inhibition promotes cone survival and visual func-
tion in rd10mice. A A schematic representation of a single intravitreal
TSA injection at PN42 followed by quantification of cones 10 days
post-injection. B Representative images of retinal cross-sections from
control and TSA-treated retinas at PN52 used to count the number of
cones (cone arrestin-labeled cones in green, DAPI-labeled nuclei in
gray). C Spider diagram showing the number of cones along the dorso-
ventral axis, corresponding to 10°, 80°, −10°, and −80° of eccentricity
from the optic nerve, respectively. D Drawing of the open filed
behavioral test used to assess cone-mediated vision. E Percentage of
time spent in the dark compartment for control and TSA-treated ani-
mals 1, 3, and 6 days post-injection (dpi). F Representative traces of
photopic ERG recordings used to evaluate cone function in wild-type,
TSA- and sham-treated rd10 retinas at PN50. G Photopic b-wave
amplitudes of control and TSA-treated rd10 mice. Data are shown as
means ± SEM (n= 5–10 animals per group). Statistical significance
was assessed using two-way ANOVA (C and E) and Mann–Whitney
nonparametric test (G), with *p < 0.05, **p < 0.01. Scale bars: 10 µm.
ONL outer nuclear layer, INL inner nuclear layer, PN postnatal day.
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pathways, we used protein-coding genes with significant
differential expression following the TSA treatment
(p ≤ 0.05), regardless of their fold change. Top molecular
pathways differentially regulated following the TSA treat-
ment included transcriptional changes of around 40 genes
belonging to PI3K-Akt and/or MAPK signaling pathways
and more than 20 genes regulating cellular senescence,
endocytosis, actin cytoskeleton, as well as cAMP and cal-
cium signaling (Fig. 6A, http://www.paintomics.org/?
jobID=4CIbSr1eA4).
The heatmap representation of the genes showing dif-
ferential expression within the PI3K-Akt cascade
(mmu04151) demonstrated the enrichment of about half of
the genes in the TSA-treated cones (23/42 genes) (Fig. 6B).
Similarly, 20 out of 36 genes were enriched within the
MAPK cascade (mmu04010). Among highly abundant
transcripts were the brain-derived neurotrophic factor
(Bdnf), and the insulin-like growth factor 1 (Igf1), growth
factors regulating MAPK and PI3K-Akt pathways. A sig-
nificantly increased Bdnf expression in the TSA-treated
cones sorted from independent samples was confirmed by
quantitative PCR (qRT-PCR), while a tendency towards
increased expression was observed for Igf1 (Figs. 6B, S6).
To determine if the survival of the TSA-treated cones was
mediated via PI3K-Akt and/or MAPK pathways, we
assessed cone survival in the rd1TN-XL explants following
the combined treatment with TSA and well-established
inhibitors of PI3K-Akt and MAPK pathways, LY294002
and U0126, respectively. U0126 blocks MAPK signaling
by inhibiting MEK1/2 [39], while LY294002 inhibits both
the PI3K-Akt pathway and autophagosome formation
[40, 41]. To avoid potential cytotoxic effects of prolonged
treatment with PI3K-Akt and MAPK inhibitors, we asses-
sed cone survival in rd1TN-XL explants after one week in
culture, but with inhibitors present only during the first
2 days. Interestingly, the TSA treatment of only 2 days
afforded the same extent of cone protection as the 7 days
treatment. Whereas LY204002 or U0126 had no effect on
cone survival in control retinas, both inhibitors significantly
decreased TSA-induced cone survival (Fig. 7A, B).
Pathway analysis also showed significant upregulation of
9/14 genes related to autophagy (mmu04140), an additional
pro-survival mechanism (Fig. 6C) [42, 43]. Significant
upregulation of the autophagy-related-5 gene (Atg5) in
surviving cones was confirmed by qRT-PCR (Figs. 6C, S6).
We also assessed the formation of autophagolysosomes in
surviving cones by quantifying the colocalized puncta
between an autophagosome marker, the microtubule-
associated proteins 1A/1B light chain 3B (LC3B), and
lysosome-associated membrane protein 1 (LAMP1) in
control and treated rd1TN-XL cones. LC3-LAMP1 staining of
retinal cross-sections from PN19-26 in vivo TSA-treated
mice showed an overall increase in both LC3- and LAMP1-
positive vesicles, as well in colocalizing puncta within the
Fig. 6 Whole genome transcriptomic analysis of TSA-induced
survival of rd1TN-XL cones. A A volcano plot representation of dif-
ferentially expressed genes as detected by RNA-seq in flow-sorted
cones from treated vs. untreated PN19-26 rd1TN-XL (n= 3 animals).
Orange and blue dots: significantly enriched and perturbed genes,
respectively, in TSA-treated cones (FDR-based, Student’s t test of
mean difference). PaintOmics analysis was used to identify differen-
tially regulated pathways in TSA-protected cones. B, C Heat maps
with hierarchical clustering of differentially expressed genes within
PI3k-Akt, MAPK, and autophagy pathways. Genes showing Student’s
t test difference between TSA and control, with p ≤ 0.05 were selected.
Bar graphs: qRT-PCR validation of differential expression of Bdnf (B)
and Atg5 (C) in FACS-sorted cones. Fold changes are relative to
controls. Data are shown as mean ± SEM (n= 4 animals). Numerical p
values by Mann–Whitney nonparametric test.
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cones in comparison to sham-treated retinas (Fig. 7C, D).
Similarly, increased LC3-LAMP1 colocalization in
cones was also detected in ex vivo treated rd1TN-XL explants
(Fig. S7).
Finally, to identify similar molecular signatures to the
expression pattern obtained in this study, we submitted our
data to the Library of Integrated Network-Based Cellular
Signatures project (LINCS) (Fig. S8) [44]. The analysis
matched our data to gene expression profiles of TSA and
vorinostat treatments on human cell lines deposited in the
LINCS platform. Of note, vorinostat is a clinically approved
pan-HDAC inhibitor from the same class as TSA. This
suggests a possibility for repurposing “off the shelf”
HDAC-inhibiting drugs for the treatment of RP.
Discussion
Cone photoreceptors are indispensable for human vision in
daylight, and their loss has devastating effects on daily tasks
and life quality [45]. Here, we show that cones have an
innate ability for survival even in the total absence of rods,
which can be induced by HDAC-driven transcriptional
changes. At the same time, HDAC inhibition may affect
other cells in the retina, which could support cone survival
in the absence of rods [46, 47]. A single intravitreal injec-
tion of HDAC inhibitor fully protected cones for one week
and significantly slowed down cone loss up to 90 days even
when all rods had already degenerated. Interestingly, the
rd1TN-XL cone loss followed exponential kinetics, as sug-
gested for other forms of neurodegeneration [48]. The
observed exponential cone loss in the rd1TN-XL retina
excludes the possibility of the cumulative damage caused
by the loss of rods and suggests that secondary dying cones
can be rescued at any time, although with the disease pro-
gression, fewer cells will be amenable for rescue. Therefore,
a treatment even at late stages of the disease is likely to be
beneficial [48]. Indeed, our data on HDAC-induced cone
protection at different stages of rd1TN-XL cone loss (PN19
and PN21) confirm this and is furthermore in line with other
Fig. 7 TSA-induced cone survival is modulated by PI3K-Akt,
MAPK, and autophagy. A Retinal cross-sections of control (top) or
TSA-treated (bottom) rd1TN-XL retinas at PN26 incubated from PN19-
PN21 with LY294002 or U0126. TN-XL cones appear green.
B Quantification of cones in the ex vivo retinas at PN26. C Repre-
sentative images from a single confocal plane on one retinal cross-
section from an rd1TN-XL mouse at PN26, sham- or TSA-injected at
PN19, with TN-XL cones (green), autophagosomes (cyan, LC3B
antibody), and lysosomes (red, LAMP1 antibody). The colocalization
of autophagosomes and lysosomes is marked with arrows. D Quanti-
fication of the number of colocalized LC3-LAMP1 (autophagolyso-
somes) puncta per cone in the ONL. Data are shown as mean ± SEM
based on 6–10 positions within retina, n= 6–8 animals in B; n= 3
animals in D. Numerical p values by Mann–Whitney nonparametric
test. Scale bars in A 20 μm, in C 10 μm. ONL outer nuclear layer, INL
inner nuclear layer.
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observations indicating that the window-of-opportunity for
the treatment of retinal dystrophies is much broader than it
is currently considered [2, 49].
Preserving retinal function in the absence of rods is the
ultimate goal of neuroprotective therapies for late-stage RP.
Recent studies suggest that therapies specifically targeting
cones at stages where most of the rods are still present could
preserve visual function in RP mouse models [3, 10]. Here
we have demonstrated an intact cone-driven retinal circuitry
in the TSA-treated rd1TN-XL retinal explants, even in the
absence of rods, by recording cone-mediated light-induced
responses from large populations of individual RGCs.
Unfortunately, the low cone number and the impaired
morphology of the remaining cones, at the stages where
rods have already fully degenerated, is a major obstacle in
assessing visual improvements by standard functional tests
like ERG [50]. While we did not detect changes in ERG-
wave amplitudes in rd1TN-XL mice treated at such late stages
of degeneration, a modest improvement of ERG recordings
was detected in rd10 mice following the treatment. Notably,
despite ERG amplitudes remaining lower than in wild-type
mice, the significant improvement in visually-driven beha-
vior suggests that the potential benefits for the daily tasks of
RP patients may be achievable even at the late stages of the
disease [51]. It is very challenging to assess the effective-
ness of vision therapy, even in patients. For example, no
improvements in ERG recordings were reported in patients
following RPE65 gene augmentation therapy, although the
useful vision was significantly increased in some patients
[52]. Even in the patient who showed a dramatic
improvement in the obstacle-path mobility test, i.e., func-
tional vision, the ERG did not differ significantly from
baseline. Therefore, it is expected that even a minor but
significant improvement in visual function by the ERG
should be positively correlated with treatment outcome.
For the treatment of retinal diseases, intravitreal injec-
tions are the preferred route of administration, as larger
volumes of a drug can be applied, and the risk of retinal
damage is reduced. However, due to an extensive retinal
circulation and the brain-retinal-barrier’s permeability for
low molecular weight compounds, intravitreally injected
TSA is cleared from the mouse eye in less than 2 h [14].
Still, a single injection led to a long-lasting cone survival,
suggesting the possibility of epigenetically induced pro-
survival mechanisms that could counteract environmental
insults caused by the absence of rods. While HDAC inhi-
bition induces changes in gene expression within minutes
[17], the effects of transcriptional regulation can persist for
months [53].
In advanced RP, cones are exposed to high oxidative
stress and inflammation [3, 4, 54] that elicit a broad range of
responses, from proliferation to cell death [55]. Our RNA-
seq data suggested changes in major pathways involved in
regulating the cellular response to oxidative stress, the
mitogen-activated protein kinases (MAPK), and phosphoi-
nositide 3-kinase activated protein kinase (PI3K-Akt)
pathways. While previous studies linked the neuroprotec-
tive effect of docosahexaenoic acid [56] and leukemia
inhibitory factor to MAPK pathway activation in rod pho-
toreceptors [57], our study highlights the role of MAPK
signaling in the prevention of secondary cone degeneration.
TSA-induced cone survival was significantly reduced by
U0126, linking cone survival in secondary cone degenera-
tion to the ERK pathway [39]. A similar reduction in cone
survival was also observed when PI3K signaling was
inhibited by LY294002, highlighting the importance of the
PI3K-Akt pathway also in cone photoreceptor survival [58].
While more specific studies are necessary to precisely
address the protective role of MAPK and PI3K-Akt acti-
vation in secondary dying cones, these results not only
validate our RNA-seq data but also suggest that HDAC
inhibition may lead to the expression of neurotrophic factors
that mediate neuroprotection via activation of these path-
ways [59, 60]. Indeed, our data suggest that an increase in
transcription of neurotrophic factors, such as Bdnf, may
contribute to cone survival. Although BDNF-induced neu-
roprotective effects on light- or mutation-induced photo-
receptor degeneration was recognized as early as 1992 by
LaVail et al. [61], our study indicates a direct upregulation
of Bdnf transcription in the cones protected from secondary
degeneration.
Cone starvation has also been recognized as one of the
main contributors to secondary cone death in RP [1, 10, 62].
Autophagy is the primary cellular mechanism for self-
nourishment and recycling of metabolites to supplement
macromolecules and energy under severe starvation [42].
The beneficial role of autophagy is demonstrated for the
clearance of misfolded proteins in mutation-affected pho-
toreceptors or dysfunctional RPE in age-related macular
degeneration (AMD) [43, 63]. Nevertheless, in secondary
cone degeneration, it remained unclear whether increased
autophagy is beneficial or not [1, 64]. The observed upre-
gulation of Atg5 transcription and an increased number of
autophagolysosomes in TSA-treated cones are in line with
the previously reported effects of HDAC inhibition on
autophagy induction [65] and highlight autophagy as a
protective mechanism in secondary cone degeneration.
In our study, a single intravitreal TSA injection afforded
a prolonged delay in cone cell death. Nevertheless, degen-
eration proceeded, albeit with slowed kinetics. This could
stem from rapid TSA degradation and/or possible off-target
effects. TSA is one of the most well-studied hydroxamate
HDAC inhibitors, reversibly inhibiting class I and II
HDACs [66]. Low nanomolar doses of TSA efficiently
inhibit HDAC in tumor and non-tumor cells [67], but as
TSA undergoes rapid metabolic degradation [68], systemic
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treatments require repeated administration [67]. Translating
our approach into a clinical application may benefit from
the development of drug delivery systems that enable a
sustained, long-term release of an HDAC inhibitor [69].
Alternatively, as a single intravitreal injection could prevent
cone degeneration for one week in mice with extremely fast
photoreceptor loss, monthly injections could have similar
effects in patients where the loss of cones spans over dec-
ades [70]. Future studies may also address the development
of more specific and effective HDAC inhibitors that may act
longer on ocular tissue. Specifically, other drugs belonging
to the group of hydroxamic acids, such as vorinostat, beli-
nostat, and panobinostat, might be of interest as we show
that clinically approved panobinostat protected cone pho-
toreceptor ex vivo to a similar extent as TSA. LINCS
analysis indicated that also vorinostat may be repurposed
for RP treatment. Notably, the clinical data already avail-
able [71] would greatly facilitate the repurposing for RP
treatment, while the side-effect profile associated with sys-
temic application in cancer therapy would likely be of lesser
concern if these drugs were used only locally in the eye.
Our previous studies showed HDAC overactivation at
the peak of photoreceptor loss in ten rodent models for
retinal dystrophies [15, 35]. Aberrant HDAC activity was
detected in photoreceptors regardless of whether underlying
mutations affect the phototransduction cascade (rd1, rd10,
Rho KO, S334ter, P23H, Cngb1 KO, Cnga3 KO, cpfl1), the
photoreceptor outer segment structure (rd2) or the visual
cycle (Rpe65 KO). This suggests that increased HDAC
activity may contribute to the mutation-related photo-
receptor cell death caused by cGMP accumulation [69],
endoplasmic reticulum stress [72, 73], or microglia activa-
tion [74]. Importantly, HDAC inhibition is also extensively
discussed as a therapeutic option for other diseases such as
cancer [75], Alzheimer’s disease [76], or Duchenne mus-
cular dystrophy [77]. Consequently, in the view of the use
of HDAC inhibition for the treatment of various diseases,
and our previous data linking HDAC overactivation to rod
loss in different mouse models of RP, this study highlights
HDACs as a common denominator of both mutation-
induced rod cell death and secondary cone degeneration and
provides a unique therapeutic option for the treatment of RP
regardless of the stage of degeneration.
Finally, detrimental environmental conditions inducing
cone loss at the late stages of RP share essential similarities
with AMD, the leading cause of blindness in the indus-
trialized world [78]. Although RPE cells are considered the
primary target for AMD pathology, loss of cone photo-
receptors in the macular region in AMD patients char-
acterizes the final stages of the disease [79]. Since RPE
dysfunction in AMD may expose cones to a milieu similar
to the one in late-stage RP, HDAC inhibition holds
significant promise also for the treatment of more common
forms of retinal degeneration.
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